EpiMedTechGlobal
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An oncology biotech developing small molecule drugs targeting epigenetic and other cancer pathways.
Oncology
Technology Platform
Small molecule drug discovery platform focused on epigenetic targets and other key oncology pathways.
Opportunities
Potential to develop novel therapies for cancers that have become resistant to existing treatments.
Risk Factors
High risk of preclinical attrition and challenge in demonstrating clinical superiority over existing standards of care.
Competitive Landscape
Operates in the highly competitive targeted oncology space, with many companies pursuing similar epigenetic mechanisms.